pharma
New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis
April 30, 2019Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis
New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …
The price of access: Can the NHS afford Orkambi?
April 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing
The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …
Sanofi and Lexicon’s Zynquista scores EU approval for type 1 diabetes patients
April 29, 2019Sales and Marketing Lexicon, Sanofi, Type 1 diabetes, Zynquista, diabetes, pharma
The European Commission has authorised the use of Sanofi and Lexicon’s Zynquista (sotagliflozin) in Europe in the treatment of specific …
AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer
April 29, 2019Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …
Gilead’s selonsertib crashes at Phase 3 in NASH
April 26, 2019Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib
Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint …
Top Ten most popular articles on Pharmafile.com this week!
April 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aduro Biotech, Cancer, GSK, ICR, J&J, JJ, Novartis, Sandoz, pharma
The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK …
Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure
April 26, 2019Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma
Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …
FDA approves Beximco’s generic version of MSD’s allergy drug Periactin
April 25, 2019Sales and Marketing FDA, MSD, Periactin, allergy, generics, pharma
Bangladesh-based Beximco Pharma is celebrating following the decision from the FDA to approve its generic version of MSD’s antihistamine therapy …
Senior GSK exec Richard Saynor revealed as new Sandoz CEO
April 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Sandoz, appointment, pharma
Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor …
Pharma boosts lobby spending in first quarter of 2019
April 24, 2019Research and Development PhRMA, Trump, USA, congress, lobbying, lobbyists, pharma
The Pharmaceutical Research and Manufacturers of America (PhRMA) trade lobbyists have spent near record levels on lobbying in the first …
Working Life: Dr Todd Hobbs, Vice President and Chief Medical Officer, Novo Nordisk
April 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, Working Life, feature, pharma
Novo Nordisk’s VP and CMO discusses his leap from family medicine into the pharma industry, his biggest achievements, and how …
AbbVie’s Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis
April 24, 2019Research and Development, Sales and Marketing AbbVie, FDA, Skyrizi, US, pharma, psoriasis
AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA …
Teva terminates Ajovy at Phase 3 in episodic cluster headache
April 24, 2019Research and Development Teva, ajovy, headache, pharma
Israeli pharmaceutical firm Teva has announced its intention to terminate further development of its calcitonin gene-related peptide (CGRP) inhibitor Ajovy …
Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer
April 23, 2019Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma
MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …
Novartis reveals promising interim Phase 3 data for gene therapy Zolgensma in spinal muscular atrophy
April 18, 2019Research and Development Novartis, Zolgensma, pharma
Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma (onasemnogene …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
